 |
Professor of Internal Medicine Professor of Human Genetics Professor of Public Health |
|
| 2017 Palmer Commons 100 Washtenaw Ave. Ann Arbor, MI 48109 -2218 |
||
Gilbert Omenn is a Professor of Internal Medicine, Human Genetics, and Public Health at the University of Michigan. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. He was formerly Dean of the School of Public Health, and Professor of Medicine and Environmental Health, University of Washington, Seattle. His research interests include cancer proteomics, chemoprevention of cancers, public health genetics, science-based risk analysis, and health policy. He was principal investigator of the beta-Carotene and Retinol Efficacy Trial (CARET) of preventive agents against lung cancer and heart disease; director of the Center for Health Promotion in Older Adults; and creator of a university-wide initiative on Public Health Genetics in Ethical, Legal, and Policy Context while at the University of Washington and Fred Hutchinson Cancer Research Center. He served as Associate Director, Office of Science and Technology Policy, and Associate Director, Office of Management and Budget, in the Executive Office of the President in the Carter Administration. He is a longtime director of Amgen Inc. and of Rohm & Haas Company. He is a member of the Council and leader of the Plasma Proteome Project for the international Human Proteome Organization. He is the President of the American Association for the Advancement of Science for 2005-2006.
Omenn is the author of 407 research papers and scientific reviews and author/editor of 17 books. He is a member of the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences, the Association of American Physicians, and the American College of Physicians. He chaired the presidential/ congressional Commission on Risk Assessment and Risk Management ('Omenn Commission'), served on the National Commission on the Environment, and chaired the NAS/NRC/IOM Committee on Science, Engineering and Public Policy. He received the John W. Gardner Legacy of Leadership Award from the White House Fellows Association in 2004.
He is active in cultural and educational organizations, and is a musician and tennis player. Omenn received his B.A. from Princeton, the M.D., magna cum laude, from Harvard Medical School, and a Ph.D. in genetics from the University of Washington.
Chinnaiyan A, Coffey D, Forrest S, Goldberg E, Holland J, Kepler T, Maley C, Mitchell M, Montie J, Morowitz H, Nelson W, Omenn G, et al. Merging bottom-up and top-down approaches to study prostate cancer biology. Complexity 2002; 7(5): 22-30.
Creighton C, Kuick R, Misek D, Rickman D, Brichory F, Rouillard JM, Omenn GS, Hanash S. Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol. 2003;4(7):R46. Epub 2003 Jun 23.
Bouwman K, Qiu J, Zhou H, Schotanus M, Mangold L, Vogt R, Erlandson E, Trenkle J, Partin AW, Misek D, Omenn GS, Haab BB, Hanash S. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003; 3: 2200-2207.
Omenn GS. The Human Proteome Organization Plasma Proteome Project Pilot Phase: Reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004;4:1235-1240.
Qiu J, Madoz-Gurpide J, Misek DE, Kuick R, Brenner DE, Michailidis G, Haab BB, Omenn GS, Hanash SM. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Research 2004; 3: 261-267.
Imafuku Y, Omenn GS, Hanash S. Proteomics approaches to identify auto-immune antibodies as cancer biomarkers. Disease Markers 2004; 20: 149-153.
Omenn GS. Advancement of biomarker discovery and validation through the HUPO Plasma Proteome Project. Disease Markers 2004; 20: 131-134.
Pedrioli PG, Eng JK, Hubley R, Vogelzang M, Deutsch EW, Raught B, Pratt B, Nilsson E, Angeletti RH, Apweiler R, Cheung K, Costello CE, Hermjakob H, Huang S, Julian RK, Kapp E, McComb ME, Oliver SG, Omenn GS, Paton NW, Simpson R, Smith R, Taylor CF, Zhu W, Aebersold R. A common open representation of mass spectrometry data and its application to proteomics research. Nat Biotechnol 2004; 22:1459-66.
Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, Kuick R, Giordano TJ, Gao W, Omenn GS, Webb CP, Hanash SM. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res 2005; 3:119-29.
Wang H, Clouthier SG, Galchev V, Misek DE, Duffner U, Min CK, Zhao R, Tra J, Omenn GS, Ferrara JL, Hanash SM. Intact-protein based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005; Feb 9 [Epub ahead of print].
Omenn GS, States DJ, Adamski MR, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson, RJ, Eddes JS, Kapp, EA, Moritz RL, Chan DW, Rai AJ, Admon A, Aebersold R, Eng J, Hancock WS, Hefta SA, Meyer H, Paik Y-K, Yoo J-S, Ping P, Pounds J, Adkins J, Qian X, Wang R, Wasinger V, Wu CY, Zhao X, Zeng R, Archakov A, Tsugita A, Beer I, Pandey A, Pisano M, Andrews P, Tammen H, Speicher DW, Hanash SH. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5:3226-3245.
Adamski, M, Blackwell T, Menon R, Martens L, Hermjakob H, Taylor C, Omenn GS, States DJ. Data management and preliminary data analysis in the pilot phase of the HUPO Plasma Proteome Project. Proteomics 2005;5:3246-3261.
Haab BB, Geierstanger BH, Michailidis G, Vitzthum F, Forrester S, Okon R, Saviranta P, Brinker A, Sorette M, Perlee L, Suresh S, Drwal G, Adkins JN, Omenn GS. Immunoassay and antibody microarray analysis of the HUPO PPP reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005;5:3278-3291.
Misek DE, Kuick R, Wang H, Galchev V, Deng B, Zhao R, Tra J, Pisano MR, Amunugama R, Allen D, Walker AK, Strahler JR, Andrews P, Omenn GS, Hanash SM. A Wide Range of Protein Isoforms in Serum and Plasma Uncovered by a Quantitative Intact Protein Analysis System (IPAS). Proteomics 2005;5:3343-3352.
Martens L, Nesvizhskii AI, Hermjakob H, Adamski M, Omenn GS, Vandekerckhove J, Gevaert K. Do we want our data raw? Including binary mass spectrometry data in public proteomics data repositories. Proteomics 2005;5:3501-3505.
Ping P, Vondriska TM, Creighton CJ, Gandhi TKB, Yang Z, Menon R, Kwon M-S, Drwal G, Kellman M, Peri S, Suresh S, Gronborg M, Molina H, Chaerkady R, Rekha B, Muthusamy B, Shet AS, Gerszten RE, Wu H, Raftery M, Wasinger V, Schulze-Knappe P, Hanash SM, Paik Y-K, Hancock WS, States DJ, Omenn GS, Pandey A. A Functional Annotation of Subproteomes in Human Plasma. Proteomics 2005;5:3506-3519.
Kapp EA, Schutz F, Connolly LM Chakel JA, Meza JE, Miller CA, Fenyo D, Eng JK, Adkins JN, Omenn GS, Simpson RJ. An evaluation, comparison and accurate benchmarking of several publicly-available MS/MS search algorithms: Sensitivity and Specificity analysis. Proteomics 2005;5:3475-3490.
Gao WM, Kuick R, Orchekowski RP, Misek DE, Qui J, Greenberg AK, Rom, WN, Brenner DE, Omenn GS, Haab BB, Hanash SM. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005;5:110 (Epub ahead of print: http://www.biomedcentral.com/1471-2407/5/110).
Bartell SM, Ponce RA, Takaro TK, Zerbe RO, Omenn GS, Faustman EM. Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention. Risk Analysis 2000;20:87-99.
Nallamothu BK, Fendrick AM, Rubenfire M, Saint S, Bandekar R, Omenn GS. Potential clinical and economic effects of homocyst(e)ine lowering. Arch Intern Med 2000;160: 3406-3412.
Bowen DJ, Thornquist M, Anderson K, Barnett M, Powell C, Goodman G, Omenn GS. Stopping the active intervention: CARET. Controlled Clinical Trials 2003; 24: 39-50.
Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS, CARET co-investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epid Biomarkers Prev 2001; 10:1069-1076.
Thornquist MD, Edelstein C, Goodman GE, Omenn GS. Streamlining IRB review in multisite trials through single-study IRB Cooperative Agreements: experience of the b-Carotene and Retinol Efficacy Trial (CARET). Controlled Clinical Trials 2002; 23: 80-86.
Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FL Jr, Omenn GS, Valanis B, Williams JH Jr. The follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst. 2004; 96: 1743-1750.
Cullen MR, Barnett MJ, Balmes JR, Cartmel B, Redlich CA, Brodkin CA, Barnhart S, Rosenstock L, Goodman GE, Hammar SP, Thornquist MD, Omenn GS. Predictors of lung cancer among asbestos-exposed men in the beta-carotene and retinol efficacy trial. Am J Epidemiol 2005;161:260-270.
Home